One To Watch

Amgen

A pioneering American biotechnology company founded in 1980, developing innovative biologics and small molecules for cancer, cardiovascular disease, obesity, inflammatory conditions, and rare diseases with products reaching patients in approximately 100 countries.

Company Overview

Amgen Inc. is one of the world's largest independent biotechnology companies, headquartered in Thousand Oaks, California. Founded on the science of living cells, Amgen discovers, develops, manufactures, and delivers innovative medicines that have transformed the treatment of serious diseases for more than four decades. The company generated approximately $35.1 billion in revenues in 2025 and employs around 28,000 people globally. Amgen's portfolio spans oncology, cardiovascular disease, inflammation, bone health, rare diseases, and, increasingly, obesity. The company is a constituent of the Dow Jones Industrial Average and the Nasdaq-100 Index, underscoring its scale and commercial significance.

Headquarters and Global Presence

Amgen is headquartered in Thousand Oaks, California, where it has maintained its primary research and corporate operations since its founding. The company has manufacturing facilities across the United States, Puerto Rico, and internationally in sites including Ireland, the Netherlands, and Singapore. Amgen maintains commercial and medical operations in approximately 100 countries worldwide, supported by regional offices across North America, Europe, Asia-Pacific, Latin America, and the Middle East. The company's global manufacturing network is renowned for its biologics production expertise, developed over more than four decades of recombinant protein manufacturing.

Founding and History

Amgen was founded on 8 April 1980 in Thousand Oaks, California, by venture capitalists led by William Bowes under the name Applied Molecular Genetics Inc. George Rathmann was appointed its first President and CEO in October 1980. The company went public on 17 June 1983. A defining scientific breakthrough came when researcher Fu-Kuen Lin's team cloned the erythropoietin gene, leading to Epogen (epoetin alfa), which revolutionised the treatment of anaemia in dialysis patients. Amgen's second landmark product, filgrastim (Neupogen), followed and became equally transformative in oncology supportive care. These pioneering biologics established Amgen as the archetype of a successful biotechnology company and funded decades of subsequent R&D investment.

Therapy Areas and Focus

Amgen's therapeutic portfolio spans oncology, cardiovascular disease, inflammation, bone health, metabolic diseases including obesity, and rare diseases. In oncology, the company pioneered T-cell engager immunotherapy with Blincyto (blinatumomab) for acute lymphoblastic leukaemia and continues to expand its haematology and solid tumour programmes. Cardiovascular disease is addressed through Repatha (evolocumab) for LDL-cholesterol reduction and olpasiran for lipoprotein(a). Obesity represents Amgen's most significant emerging therapeutic area through MariTide, a monthly injectable being investigated across obesity-related comorbidities. Inflammation is served by Otezla (apremilast) for psoriasis and psoriatic arthritis, while rare disease programmes address bone disorders and other conditions.

Technology Platforms and Modalities

Amgen's technological foundations lie in recombinant protein biologics, built on decades of expertise in mammalian cell culture manufacturing. In oncology, the company has developed BiTE (Bispecific T-cell Engager) technology, exemplified by Blincyto and next-generation multispecific antibodies in development. Amgen's MariTide combines a GIP receptor antibody with GLP-1 receptor agonist peptides, representing an innovative multi-receptor targeting approach for obesity. In cardiovascular disease, olpasiran employs RNA interference (RNAi) to reduce lipoprotein(a) synthesis. The January 2026 acquisition of Dark Blue Therapeutics added targeted protein degradation capability through small molecules directed at MLLT1/3 in acute myeloid leukaemia. Amgen also has molecular glue and CELMoD technology through its mezigdomide programme in multiple myeloma.

Key Pipeline and Programs

MariTide (maridebart cafraglutide), Amgen's anti-obesity candidate, is in multiple Phase 3 trials for obesity, type 2 diabetes, and obesity-related comorbidities including heart failure and chronic kidney disease; its potential for monthly or quarterly dosing represents a key differentiator. Mezigdomide, a second-generation CELMoD agent, is in two global Phase 3 trials for relapsed/refractory multiple myeloma. Olpasiran, an RNAi agent targeting lipoprotein(a), is in late-stage cardiovascular development. Blincyto is being evaluated in a Phase 3 trial as a subcutaneous formulation. The acquisition of Dark Blue Therapeutics brought a MLLT1/3 degrader for acute myeloid leukaemia into early development. Amgen's pipeline includes 17 Phase 3 programmes, eight in Phase 2, and 19 in Phase 1.

Key Personnel

Robert A. Bradway has served as Chairman and Chief Executive Officer since 2013, providing over a decade of strategic continuity to one of biotechnology's largest companies. James Bradner, M.D., joined as Executive Vice President, Research and Development and Chief Scientific Officer, bringing expertise in epigenetics and cancer biology. David M. Reese, M.D., serves as Executive Vice President and Chief Technology Officer, overseeing manufacturing and global development operations. John Tsai, M.D., serves as Chief Medical Officer and Senior Vice President of Global Medical. Peter Griffith serves as Executive Vice President and Chief Financial Officer. The leadership team has been strengthened by executive appointments specifically focused on accelerating innovation across oncology, cardiovascular, and metabolic programmes.

Strategic Partnerships

Amgen's most significant 2026 partnership activity includes the January 2026 acquisition of Dark Blue Therapeutics for up to $840 million, bolstering its acute myeloid leukaemia oncology pipeline. The company launched its Amgen Partners of Choice oncology network in 2025, connecting eight elite cancer research institutions including Dana-Farber Cancer Institute, Memorial Sloan Kettering, and Gustave Roussy. Amgen has an ongoing collaboration with MediLink for the antibody-drug conjugate YL201 and with Asher Biotherapeutics for etakafusp alfa. A collaboration with Xencor on multispecific antibodies remains active. The company is terminating its rocatinlimab programme collaboration with Kyowa Kirin, with Kyowa Kirin assuming full ownership. Amgen's biosimilar business, launched through partnerships with AstraZeneca, represents a significant element of its diversified commercial strategy.

FAQ Section

Amgen's central strategic issue is whether MariTide, its monthly injectable anti-obesity candidate, can establish a meaningful clinical and commercial differentiation from the entrenched weekly GLP-1 receptor agonist market led by Novo Nordisk and Eli Lilly, while simultaneously sustaining momentum across its broad oncology and cardiovascular pipeline.

Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting approximately one in five people globally, and until olpasiran and similar RNA-based agents, no approved therapy could substantially reduce Lp(a) levels, making it one of the most significant residual unmet needs in cardiovascular disease prevention.

Amgen differentiates itself through its unique combination of pioneering BiTE T-cell engager immunotherapy technology, a multi-receptor obesity platform with MariTide, RNAi cardiovascular medicine with olpasiran, and protein degradation capabilities, supported by one of the most experienced biologics manufacturing organisations in the industry.

MariTide's potential for once-monthly or even less frequent dosing compared with the current standard of weekly injections for GLP-1 therapies could substantially improve patient adherence and convenience in obesity treatment, a market projected to reach hundreds of billions of dollars globally.

Amgen's pipeline is defined by oncology—spanning haematology and solid tumours through BiTE and CELMoD platforms—cardiovascular disease via Lp(a) and LDL reduction programmes, obesity and metabolic diseases through MariTide, and inflammation, with 17 programmes in Phase 3, eight in Phase 2, and 19 in Phase 1.

Amgen is a fully commercial, large-cap biotechnology company generating over $35 billion annually in revenues, with an extensive marketed portfolio and one of the deepest industry pipelines, currently in a pivotal expansion phase driven by obesity, oncology, and cardiovascular innovations.

Key watchpoints include Phase 3 data readouts for MariTide across obesity-related comorbidities, Phase 3 results for mezigdomide in multiple myeloma, the clinical and commercial progression of olpasiran for elevated Lp(a), and integration of the Dark Blue Therapeutics programme in acute myeloid leukaemia.

Want to Update your Company's Profile?